Windward Bio filed for a Nasdaq initial public offering, aiming to fund China-derived assets and in-house R&D. The Basel-based company is a relatively early-stage biotech with two clinical-stage assets, according to the filing news. The IPO attempt adds to a steady stream of public-market bids from Europe-based life-science companies seeking U.S. liquidity and capital for late preclinical and clinical execution. Windward’s emphasis on China-origin pipeline assets also highlights how geography continues to shape investor attention in biotech financing. For the sector, IPOs like this are a near-term indicator of how open public markets remain to mid-cap and clinical-stage biotech risk profiles.